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Abstract
Background: The highest priority in preventive cardiology was given to patients with estab-
lished coronary artery disease (CAD). The aim of the study was to assess the implementation 
of guidelines for secondary prevention in everyday clinical practice by evaluating control of the 
main risk factors and the cardioprotective medication prescription rates for patients, following 
their hospitalization for CAD.
Methods: Five hospitals with cardiology departments serving the city and its surround-
ing districts in southern part of Poland participated in the study. Consecutive patients aged  
≤ 80 years, hospitalized from January 1 2010 to April 31 2012 due to an acute coronary 
syndrome or for a myocardial revascularization procedure were recruited and interviewed  
6–18 months after hospitalization.
Results: The medical records of 595 patients (mean age: 62.8 ± 9.0 years, 397 men and 
198 women) were reviewed and included in the analyses. Proportions of medical records with 
available information on risk factors were high with the exception of total cholesterol levels as 
well as weight and height measurements, which were available in less than 80% of the hospital 
records. The prescription rate at discharge for antiplatelets was 99%, beta-blockers (BB) — 
85%, angiotensin converting enzyme inhibitors (ACEI) or sartans — 85%, and lipid-lowering 
drugs — 94%. Patients scheduled for coronary artery bypass grafting were significantly less of-
ten prescribed BB, ACEI or sartans, and lipid-lowering drugs. The proportion of patients with 
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LDL cholesterol level (≥ 1.8 mmol/L) 73%, and with a high HbA1C level (≥ 7.0%) 14%, whereas 
20% of participants were smokers and 80% were overweight. The proportion of patients taking 
an antiplatelet agent 6–18 months after hospitalization was 90%, BB — 82%, ACEI — or 
sartan 78%, and lipid-lowering drug — 82%. Overall, 33.9% of the study participants declared 
that they had been advised to participate in a rehabilitation/secondary prevention program 
following their hospitalization and 30.5% participated in a rehabilitation/secondary preven-
tion program. However, only 28.2% took part in at least half of the planned sessions. Using  
a multivariate analysis we showed that, in general, risk factors control and the prescription rates 
of cardioprotective medications were related to the patients’ age, education, and participation in 
a rehabilitation/secondary prevention program following their hospitalization due to CAD.
Conclusions: Our data provide evidence that there is a considerable potential for further 
reduction of cardiovascular risk in CAD patients. Our results suggest that increasing patient 
participation rates in rehabilitation/secondary prevention programs may improve the imple-
mentation of the secondary prevention. (Cardiol J 2015; 22, 2: 219–226)
Key words: coronary artery disease, risk factors, secondary prevention,  
smoking, hypertension, hypercholesterolemia
Introduction
Coronary artery disease (CAD) is the most 
common single cause of death in developed coun-
tries [1]. In Poland, the standardized death rate 
from ischemic heart disease in people under 
65 years of age is 24 per 100,000 and the number of 
ischemic heart disease deaths is 45,000 yearly [2, 3]. 
In recent years, rapid development in pharmaco-
logical as well as invasive CAD treatment methods 
has been observed. Nevertheless, the results of 
a mortality follow-up of the European Action on 
Secondary Prevention through Intervention to Re-
duce Events (EUROASPIRE) I–III surveys indicate 
that risk factors remain independent predictors of 
cardiovascular mortality in CAD patients [4]. The 
conclusion from another 5-year follow-up survey 
is that smoking cessation, providing advice on diet 
and ensuring optimal pharmacological treatment 
are crucial factors in reducing mortality in patients 
who have suffered myocardial infarction (MI) [5]. 
Thus, the highest priority for preventive cardiology 
was given to patients with established CAD [6].
The Cracovian Program for Secondary Preven-
tion of Ischemic Heart Disease was launched in 
1996 [7, 8]. The main goal of the program was to as-
sess and improve the quality of medical care in the 
field of secondary CAD prevention. Later, the same 
centers took part in the EUROASPIRE surveys [9]. 
These projects allowed the assessment of temporal 
changes in the implementation of recommenda-
tions as well as international comparisons [9–11]. 
However, not much is known about the relation 
between types of acute coronary syndrome (MI vs. 
unstable angina [UA]) and the quality of secondary 
prevention in Poland. It is also not known whether 
CAD patients who have undergone a myocardial 
revascularization procedure receive better quality 
medical care than non-revascularized patients. The 
aim of the present study was to assess the recent 
status of implementation of the guidelines for sec-
ondary prevention in everyday clinical practice by 
assessing control of the main risk factors and the 
cardioprotective medication prescription rates in 
patients after hospitalization for CAD.
Methods
The study groups and the methods used in 
the Cracovian Program for Secondary Preven-
tion of Ischemic Heart Disease and Polish part of 
EUROASPIRE surveys were described in earlier 
reports [10, 11]. A brief description is given below.
Five hospitals with cardiology departments, 
serving the city and its surrounding districts in the 
southern part of Poland participated in the study. 
Total population of this area is about 1,200,000 
inhabitants. In each department, medical records 
of consecutive patients hospitalized from January 1 
2010 to April 31 2012 due to acute MI (first or 
recurrent, no prior percutaneous coronary inter-
vention [PCI] or coronary artery bypass grafting 
[CABG]), UA (first or recurrent, no prior PCI or 
CABG), PCI (first, no prior CABG) or scheduled 
for CABG (first) were reviewed and patients aged ≤ 
80 years were identified retrospectively excluding 
those who had died during their in-hospital stay 
and those who were scheduled for CABG combined 
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with valve surgery. If a patient was hospitalized 
more than once within the study period, only the 
first hospitalization was accepted as an index event. 
The medical records of patients fulfilling the inclu-
sion criteria were analyzed using the standardized 
data collection form.
Participants were invited to take part in the 
follow-up examination 6–18 months after dis-
charge. Data on demographic characteristics, 
personal history of CAD, smoking status, blood 
pressure, fasting glucose, plasma lipids, and pre-
scribed medications were obtained using a stand-
ardized data collection form. The patients’ height 
and weight were measured in a standing position 
without shoes and heavy outer garments using 
standard scales with a vertical ruler. Body mass 
index (BMI) was calculated according to the fol-
lowing formula: BMI = weight [kg]/(height [m])2. 
Blood pressure was measured twice, on the right 
arm in a sitting position after at least 5 min of rest. 
For plasma lipid and glucose measurements a fast-
ing venous blood sample was taken between 7:30 
and 8:30 in the morning. For the present report, 
results of the analyses which were done no later 
than 4 h after blood collection were used. Low 
density lipoprotein-cholesterol (LDL-C) levels 
were calculated according to Friedewald formula.
We also calculated the secondary prevention 
coefficient: for each risk factor controlled (not 
smoking, blood pressure < 140/90 mm Hg, LDL-C 
< 1.8 mmol/l, glycated hemoglobin [HbA1c] < 7.0%, 
BMI < 25 kg/m2) during the follow-up interview 
one point was given. Additionally, one point was 
given for taking an antiplatelet agent and an an-
giotensin converting enzyme inhibitor (ACEI) or 
a sartan. Thus, the secondary prevention coefficient 
could vary from 1 to 7. The survey protocol was 
approved by the institutional Bioethics Committee.
Statistical analysis
Categorical variables were reported as per-
centages and continuous variables as means 
± standard deviation. The Pearson c2 test was applied 
to all categorical variables. Normally distributed 
continuous variables were compared by using the 
Student’s t test or analysis of variance. Variables 
without normal distributions were evaluated using 
the Mann-Whitney U test or the Kruskal-Wallis 
analysis of variance. Stepwise multivariate analysis 
was performed using the multivariate regression 
analysis as implemented in the STATISTICA 8.0 
software (StatSoft INC., Tulsa, USA). Adjusted 
R2 statistic was used as an indicator of the best 
statistical model. A 2-tailed p value < 0.05 was 
regarded as indicating statistical significance.
Results
The medical records of 595 patients were 
reviewed and included in the analyses. The mean 
age, sex and proportion of men to women by survey 
are presented in Table 1. The patients from the PCI 











Age [years] 62.8 ± 9.4 63.2 ± 9.0 61.0 ± 7.7 65.9 ± 8.2 < 0.05 62.8 ± 9.0
Sex: < 0.05
Men 66.3% 58.6% 78.8% 78.9% 66.7%
Women 33.7% 41.4% 21.2% 21.1% 33.3%
Duration of education* [years] 11.5 ± 3.2 12.4 ± 3.6 11.3 ± 2.8 11.3 ± 3.1 0.08 11.8 ± 3.3
Practice setting*: 0.23
Hospital outpatient clinics 57.4% 53.2% 46.9% 57.7% 53.8%
Outpatient clinics 29.1% 34.7% 39.5% 38.5% 33.8%
Private cardiology practices 8.8% 10.5% 13.6% 3.9% 10.0%
No regular health check-up 4.7% 1.6% 0.0% 0.0% 2.4%
Specialization of the physician*: 0.31
Cardiologist 87.2% 93.5% 85.2% 96.2% 89.4%
General practitioner 12.2% 5.5% 14.8% 3.8% 10.3%
Not known 0.7% 0.0% 0.0% 0.0% 0.3%
Employed* 20.3% 17.1% 25.9% 19.2% 0.50 20.4%
*Among subjects who participated in the follow-up examination, as declared by the patients; CABG — coronary artery bypass grafting;  
MI — myocardial infarction; PCI — percutaneous coronary intervention; UA — unstable angina
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group were the youngest, whereas the proportion 
of women was the highest in the UA group.
The proportions of medical records with avail-
able information on risk factors are presented in 
the Table 2. We found no major differences in 
the proportions of medical records with available 
information on risk factors between index diag-
noses with the exception of weight and height. 
The proportion of medical records with available 
information on weight and height was significantly 
lower in the CABG and MI groups when compared 
with the other index diagnoses. Cardioprotective 
drugs prescription rates at discharge are shown 
in Table 3. The prescription rate of beta-blockers 
(BB), ACEI or sartans, calcium antagonists, lipid-
-lowering drugs, and anticoagulants differed be-
tween the index diagnoses, whereas the prescrip-
tion rate of antiplatelets and diuretics were similar 
across groups.
Out of the 595 invited patients 380 (63.9%) 
participated in the follow-up examination 6–18 
months after discharge from hospital. The partici-
pation rate differed significantly across the index 
events: MI group — 55.4%, UA group — 65.4%, PCI 
group — 81.8%, CABG group — 68.4% (p < 0.05). 
No significant differences were found between 
men and women (63.5% vs. 64.6%, p = NS). There 
were no significant differences in mean age of those 
who underwent a follow-up examination and those 
who did not (62.6 ± 8.6 years vs. 63.2 ± 9.7 years, 
p = NS).
The study participants did not differ signifi-
cantly between the index events in respect of the 
duration of education, employment, practice set-
ting, and the specialization of the physician decid-
ing on the course of management (Table 1). Overall, 
33.9% of the study participants declared they had 
been advised to participate in a rehabilitation/
secondary prevention program following the index 
hospitalization (MI 39.2%, UA 32.8%, PCI 21.0%, 
CABG 50.0%; p < 0.05) and 30.5% participated 
in a rehabilitation/secondary prevention program 
following the index hospitalization. However, only 
28.2% took part in at least half of the planned ses-
sions (MI 32.4%, UA 25.6%, PCI 17.3%, CABG 
50.0%; p < 0.05).
We found that 20.3% of the participants 
smoked, 47.2% had high blood pressure, 72.8% 
Table 2. Proportions of hospital records with available information on risk factors.
MI UA PCI CABG P Total
Smoking* 92.5% 88.5% 95.0% 92.1% 0.25 91.6%
Hypertension* 96.6% 97.9% 96.0% 97.4% 0.77 97.0%
Blood pressure** 98.9% 98.4% 96.0% 100.0% 0.21 98.3%
Dyslipidemia* 84.35 82.2% 92.9% 89.5% 0.08 85.4%
Total cholesterol** 75.7% 78.0% 66.7% 73.7% 0.20 74.8%
Diabetes* 98.5% 100.0% 98.0% 100.0% 0.26 99.0%
Weight and height** 61.8% 73.8% 98.0% 52.6% < 0.001 71.1%
*Any information in the medical record about risk factor prior to hospitalization; **Measurement during hospitalization; CABG — coronary 
artery bypass grafting; MI — myocardial infarction; PCI — percutaneous coronary intervention; UA — unstable angina
Table 3. Prescription rates of cardioprotective drugs at discharge.
MI UA PCI CABG P Total
Antiplatelets 99.3% 99.0% 100.0% 100.0% 0.72 99.3%
Beta-blockers 83.2% 84.8% 95.0% 76.3% 0.01 85.2%
ACEI/sartans 79.8% 89.0% 97.0% 73.7% < 0.001 85.2%
Calcium antagonists 20.2% 31.4% 23.2% 18.4% 0.04 24.2%
Diuretics 36.0% 43.5% 45.5% 39.5% 0.26 40.2%
Lipid lowering drugs 92.1% 95.8% 99.0% 84.2% < 0.01 93.9%
Antidiabetic agents 28.5% 23.0% 30.3% 34.2% 0.35 27.4%
Anticoagulants 24.3% 23.0% 9.1% 34.2% < 0.01 22.0%
ACEI — angiotensin converting enzyme inhibitors; CABG — coronary artery bypass grafting; MI — myocardial infarction; PCI — percutaneous 
coronary intervention; UA — unstable angina
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high LDL-C level, 13.9% had HbA1c ≥ 7.0%, and 
37.8% were obese 6–18 months after discharge 
(Table 4). No significant relation between the 
index events and the control of risk factors was 
found. Proportion of patients taking antiplatelets, 
BB, ACEI/sartans, diuretics, lipid-lowering drugs, 
and antidiabetic agents did not differ significantly 
between the index groups (Table 5). The only sig-
nificant difference was higher proportion of patients 
from the UA group taking calcium antagonists as 
compared with the MI group (p < 0.01), and higher 
proportion of CABG participants taking anticoagu-
lants when compared with the MI (p < 0.05) and 
UA (p < 0.05) groups.
The proportions of smokers being ever in-
structed on methods of smoking cessation are 
presented in Table 6, whereas the proportions of 
patients being ever instructed in healthy diet are 
presented in Table 7. The study groups did not 
differ in proportions of participants instructed in 
smoking cessation methods or healthy diet.
The mean secondary prevention coefficient 
was 4.35 ± 1.08. In the univariate analysis, the 
secondary prevention coefficient was related 
Table 4. Proportions of patients who did not reach treatment goals 6–18 months after discharge.
MI UA PCI CABG P Total
Smoking 17.6% 22.4% 22.2% 19.2% 0.75 20.3%
BP ≥ 140/90 mm Hg 43.5% 46.3% 54.3% 50.0% 0.47 47.2%
LDL-C ≥ 1.8 mmol/L 71.1% 72.6% 73.8% 80.0% 0.83 72.8%
HbA1c ≥ 7.0% 16.2% 13.3% 15.0% 8.6% 0.20 13.9%
BMI ≥ 25 kg/m2 79.1% 80.5% 84.0% 76.9% 0.80 80.4%
BMI ≥ 30 kg/m2 38.5% 40.7% 39.5% 15.4% 0.11 37.8%
BMI — body mass index; BP — blood pressure; HbA1c — glycated hemoglobin; LDL-C — low density lipoprotein cholesterol; CABG — coro-
nary artery bypass grafting; MI — myocardial infarction; PCI — percutaneous coronary intervention; UA — unstable angina
Table 5. Proportions of patients taking cardioprotective drugs 6–18 months after discharge from hospital.
MI UA PCI CABG P Total
Antiplatelets 91.9% 84.8% 93.8% 88.5% 0.13 89.7%
Beta-blockers 80.8% 77.7% 88.9% 88.5% 0.15 81.8%
ACEI/sartans 76.4% 81.6% 76.5% 76.9% 0.73 78.2%
Calcium antagonists 17.6% 31.2% 22.2% 19.2% 0.06 23.2%
Diuretics 37.2% 45.6% 40.7% 38.5% 0.56 40.8%
Lipid lowering drugs 83.1% 76.8% 87.7% 88.5% 0.18 82.4%
Antidiabetic agents 26.4% 27.3% 35.4% 32.0% 0.50 29.0%
Anticoagulants 4.9% 5.0% 10.1% 16.0% 0.10 6.8%
ACEI — angiotensin converting enzyme inhibitors; CABG — coronary artery bypass grafting; MI — myocardial infarction; PCI — percutaneous 
coronary intervention; UA — unstable angina
Table 6. Proportions of smokers (before the index hospitalization or at the time of the follow-up exami-
nation) being ever instructed by a physician on smoking cessation (as declared by the patients). 
MI UA PCI CABG P Total
Oral advice 68.5% 74.4% 63.6% 44.4% 0.36 67.7%
Advice using printed materials 31.4% 34.3% 36.4% 33.3% 0.98 33.3%
Referral to a smoking cessation clinic 22.2% 20.6% 22.7% 12.5% 0.93 21.1%
Nicotine replacement therapy 11.1% 20.6% 13.6% 0.0% 0.38 13.6%
Bupropion or varenicline 11.1% 9.1% 4.6% 0.0% 0.63 8.3%
Advice on other methods 11.4% 8.8% 4.6% 0.0% 0.62 8.3% 
CABG — coronary artery bypass grafting; MI — myocardial infarction; PCI — percutaneous coronary intervention; UA — unstable angina
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to participation in the rehabilitation/secondary 
prevention program following the index hospital-
ization, yet not to the index event (Table 8). In 
a multivariate model, the secondary prevention 
coefficient was related to the patient’s age, educa-
tion and participation in a rehabilitation/secondary 
prevention program following the index hospitaliza-
tion (Table 9).
Discussion
In general, our results did not show a big 
improvement in the management of patients after 
hospitalization for CAD as compared to the previ-
ous survey which was finished in 2012 [11]. As 
in the previous surveys we found considerable 
potential for further reduction of cardiovascular 
risk in CAD patients [8, 10, 11].
Unfortunately, no study published in recent 
years was designed to assess secondary prevention 
of CAD outside Krakow. However, some recently 
published data from registries of patients hospital-
ized due to acute coronary syndromes are available 
[12, 13]. In a nation-wide registry of acute coronary 
syndrome hospitalizations it was estimated that 
the average prescription rate at discharge for as-
pirin and lipid lowering agents was slightly below 
90%, and for BB and ACEI below 80% [12]. In 
3,564 patients hospitalized for ST-elevation MI in 
Greater Poland, the prescription rates were 96% 
for antiplatelet agents, 74% for BB, 58% for ACEI 
and 90% for statins [13]. It should be stressed 
that the prescription rates of cardiopreventive 
medications in Poland are similar to the average 
prescription rates in centers participating in the 
EUROASPIRE III Survey [9], and much higher 
compared to centers from high-income countries 
participating in the PURE Study [14].
The present results confirm the observations 
of the survey carried out in 2006–2007 which sug-
gested no major sex-related difference in the pro-
Table 8. The secondary prevention coefficient 
(SPC) values according to subgroups of patients. 
Subgroup SPC P
Age: 0.14
< 60 years 4.24 ± 1.11
60–70 years 4.33 ± 1.07
≥ 70 years 4.54 ± 1.05
Sex: 0.14
Men 4.41 ± 1.06
Women 4.24 ± 1.09
Duration of education: 0.09
≤ 11 years 4.27 ± 1.09
> 11 years 4.47 ± 1.08
Index diagnosis: 0.58
Myocardial infarction 4.41 ± 1.16
Unstable angina 4.36 ± 1.08
PCI 4.21 ± 0.94
CABG 4.46 ± 1.14
Practice setting: 0.37
Hospital outpatient clinics 4.42 ± 1.08
Outpatient  clinics  4.21 ± 1.07
Private cardiology practices 4.48 ± 1.03
No regular health check-up 4.38 ± 1.51
Specialization of the physician: 0.08
Cardiologist 4.39 ± 1.10
General practitioner 4.05 ± 0.97
Professionally active 4.34 ± 0.97 0.93




Participated 4.55 ± 1.10
Not participated 4.28 ± 1.07
Total 4.35 ± 1.08
CABG — coronary artery bypass grafting, PCI — percutaneous 
coronary intervention
Table 7. Proportions of patients being ever instructed by a physician in healthy diet (as declared by the 
patients). 
MI UA PCI CABG P Total
Reduction of salt intake 73.8% 78.7% 81.5% 80.8% 0.54 77.5%
Reduction of fat intake 80.7% 84.4% 87.7% 88.5% 0.50 84.0%
Increase in unsaturated fats intake 77.4% 81.2% 86.4% 88.5% 0.29 81.3%
Reduction of calories intake 71.2% 76.2% 70.4% 76.9% 0.71 73.1%
Increase in vegetables and fruits intake 78.1% 79.5% 86.4% 84.6% 0.44 80.8%
Increase in fish intake 67.8% 68.9% 77.8% 80.8% 0.26 71.2%
CABG — coronary artery bypass grafting; MI — myocardial infarction; PCI — percutaneous coronary intervention; UA — unstable angina
portions of patients who achieved recommended 
treatment targets in secondary prevention [15]. We 
also showed that older patients (age ≥ 70 years) 
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Table 9. Variables related to the value of the secondary prevention coefficient in the multivariate analysis.
Beta ± standard error P
Age [years] 0.15 ± 0.05 0.01
Participation in a rehabilitation/secondary prevention program  
following the index hospitalization (yes: 1, no: 0)
0.11 ± 0.05 < 0.05
Duration of education [years] 0.11 ± 0.05 < 0.05
Sex (male: 1, female: 0) 0.08 ± 0.05 0.11
Practice setting (outpatient clinics: 1, other practice settings: 0) –0.07 ± 0.05 0.18
Specialization of the physician (cardiologist: 1, general practitioner: 0) 0.06 ± 0.05 0.24
smoked less frequently compared to patients aged 
< 60 [15]. On the other hand, fewer patients aged 
≥ 70 years had blood pressure < 140/90 mm Hg 
when compared with younger subjects. No major 
age-related difference in respect to the other main 
risk factors or prescriptions rates of cardioprotec-
tive medications was found [15]. Indeed, the present 
results confirm that in general, older age (at least 
up to 80 years) is not related to lower standard of 
medical care in the field of secondary prevention.
It should be emphasized that the present re-
sults still suggest insufficient control over all main 
cardiovascular risk factors. As one of the important 
determinants of reaching the treatment targets is 
participation in the secondary prevention/cardiac 
rehabilitation programs, the finding that the low 
and decreasing proportion of patients had been 
advised to participate in the secondary prevention 
program/cardiac rehabilitation does not allow be-
ing optimistic. Indeed, in the previous report we 
showed that the proportion of patients who were 
advised to participate in such programs was 53.9% 
in 2005–2006 and 47.1% in 2010–2011, whereas 
the proportions of patients who finally participated 
in a rehabilitation/secondary prevention program 
were 35.9% and 33.3%, respectively [11]. It was 
shown that such programs result in better control 
of risk factors and improve prognosis [16–18]. 
Indeed, it seems that a higher participation rate 
in the secondary prevention/cardiac rehabilitation 
programs could result in better control of risk fac-
tors. Itshould be also stressed that the improved 
cooperation between hospital and outpatient clinic 
staff, as well as better access to a cardiologist in 
case of any suspicion of heart-related problems 
could further improve the patients’ prognosis. 
Recently, experts from the Polish Cardiac Society 
described the “Optimal Model of Comprehensive 
Rehabilitation and Secondary Prevention”, wide 
implementation of which in Poland could be related 
to a decrease in the number of deaths by 3,389, 
in the number of MIs by 3,872, in the number of 
myocardial revascularization procedures by 13,499, 
and in the number of cardiac hospitalizations by 
23,182 yearly [19].
Limitations of the study
The present study has some limitations. 
Firstly, we were unable to assess the impact of 
secondary prevention guidelines on the risk of 
cardiovascular complications. Secondly, our study 
participants were not representative of all CAD 
patients. Participants were limited to those who 
had experienced an acute CAD event or had under-
gone a revascularization procedure. Therefore, our 
results should not be directly applied to other CAD 
patients. Finally, we did not analyze the doses of 
cardioprotective drugs taken by the patients. It is 
possible that blood pressure, cholesterolemia, and 
glycemia were not controlled in some cases due to 
insufficient doses of the drugs prescribed. It should 
also be pointed out that we had no information on 
the patients’ compliance with instructions regard-
ing prescriptions. It is reasonable to suspect that 
some patients had been taking their medications 
irregularly.
Conclusions
Our data provide evidence that there is 
a considerable potential for further reduction of 
cardiovascular risk in CAD patients. Our results 
suggest that increasing the participation rate in 
rehabilitation/secondary prevention programs 
may improve the implementation of the secondary 
prevention guidelines.
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